MannKind Completes Acquisition of scPharmaceuticals
MannKind Corporation has successfully acquired scPharmaceuticals Inc., a move expected to diversify MannKind's revenue growth, particularly through the FUROSCIX® product for heart and kidney disease. This acquisition strengthens MannKind's commercial and medical capabilities, adding FUROSCIX to its existing portfolio which includes Afrezza® and V-Go®, positioning it as a growth-focused biopharmaceutical company in cardiometabolic care. The transaction, valued at $5.35 per share in cash plus a contingent value right, aims to expand MannKind's market reach and support its late-stage pipeline development.
MannKind Expands Cardiometabolic and Lung Portfolio with $360 Million Acquisition of scPharmaceuticals
MannKind Corporation is set to acquire scPharmaceuticals Inc. for up to $360 million, significantly expanding its presence in cardiometabolic and orphan lung diseases with the addition of FDA-approved Furoscix. This acquisition, supported by a $500 million strategic financing agreement with Blackstone, aims to accelerate MannKind's revenue growth and diversify its product offerings. The deal is expected to close in Q4 2025, positioning MannKind for continued double-digit growth.
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases
MannKind Corporation announced a definitive merger agreement to acquire scPharmaceuticals Inc. for an upfront cash payment of $5.35 per share plus a contingent value right up to $1.00, totaling up to $6.35 per share. This acquisition expands MannKind's presence into cardiorenal medicine with scPharmaceuticals' FDA-approved FUROSCIX, aiming to diversify revenue streams, accelerate double-digit growth, and leverage existing infrastructures for enhanced market reach in cardiometabolic and lung diseases. The transaction is expected to close in the fourth quarter of 2025.
Cooley, Latham Lead $360M ScPharmaceuticals Acquisition
MannKind, advised by Cooley LLP, announced plans to acquire scPharmaceuticals, represented by Latham & Watkins LLP, in a deal valued at up to $360 million. This acquisition highlights activity in the biopharmaceutical sector with significant legal counsel from both firms.
MannKind Corporation to Acquire scPharmaceuticals: More Details Inside
MannKind Corporation is set to acquire scPharmaceuticals Inc. for up to approximately $360 million, offering $5.35 per share in cash plus a contingent value right up to $1. The acquisition aims to expand MannKind's presence in cardiorenal medicine with scPharmaceuticals' FDA-approved Furoscix, used for chronic heart failure and kidney disease. The deal is expected to close in Q4 2025, with scPharmaceuticals stock seeing a positive market reaction.
scPharmaceuticals Inc. (NASDAQ:SCPH) Soars 26% But It's A Story Of Risk Vs Reward
scPharmaceuticals Inc. (NASDAQ:SCPH) shares have gained 26% in the last month, bringing its 12-month gain to 12%. Despite strong recent revenue growth of 138% and analyst forecasts predicting 72% annual growth over the next three years, the company's P/S ratio of 6.2x is similar to the industry median of 5.4x. This suggests that investors might be skeptical about the sustainability of its future growth, as the P/S ratio doesn't reflect its superior revenue outlook.
scPharmaceuticals (NASDAQ:SCPH) adds US$26m to market cap in the past 7 days, though investors from five years ago are still down 41%
scPharmaceuticals (NASDAQ:SCPH) saw its market cap increase by US$26 million in the past week, driven by a 93% share price rise in the last quarter. Despite this recent surge, long-term investors from five years ago are still down 41%, underperforming an index fund. The company has shown strong 85% annual revenue growth over five years but remains unprofitable, indicating market focus is on top-line growth.
Shareholders Will Likely Find scPharmaceuticals Inc.'s (NASDAQ:SCPH) CEO Compensation Acceptable
scPharmaceuticals Inc.'s CEO, John Tucker, received total compensation of US$2.4 million in 2024, which is below the industry median for similar-sized pharmaceutical companies. Despite a 31% increase from the previous year, shareholders have experienced a 31% loss over three years and a 19% annual EPS decline. The company's Annual General Meeting on June 3rd will allow shareholders to voice concerns regarding performance and executive compensation.
Earnings call: scPharmaceuticals reports robust Q3 growth, eyes FDA nod
scPharmaceuticals reported a 24% increase in net revenue for Q3 2024, reaching $10 million, driven by sales force expansion and broader indication for FUROSCIX. Despite a net loss of $35.1 million, the company's cash reserves rose to $91.5 million from a recent financing round. They are also preparing for potential FDA approval of FUROSCIX for chronic kidney disease patients, with a PDUFA date set for March 6, 2025.
scPharmaceuticals Announces Non-Dilutive Financings Totaling Up to $125 Million with Perceptive Advisors
scPharmaceuticals announced non-dilutive financings totaling up to $125 million with Perceptive Advisors. The funding includes $75 million at close through debt and royalty financings, with access to an additional $50 million, and a refinancing of existing debt under more favorable terms. These proceeds will support the ongoing commercialization of FUROSCIX, a treatment for congestion due to fluid overload in adult heart failure patients.
FDA Approves Wearable Furosemide Delivery System Furoscix for Outpatient Use
The FDA has approved Furoscix (furosemide injection), a wearable furosemide delivery system, for outpatient treatment of congestion due to fluid overload in adult patients with NYHA Class II and Class III chronic heart failure. This system allows for self-administration of subcutaneous furosemide at home, providing a new option for patients whose oral diuretics are no longer effective. The product is expected to launch in the first quarter of 2023.
scPharmaceuticals Announces Data Presentations at the Heart Failure Society of America 2022 Annual Scientific Meeting
scPharmaceuticals Inc. announced two poster presentations at the Heart Failure Society of America 2022 Annual Meeting, highlighting the potential clinical benefits of managing heart failure congestion with FUROSCIX (furosemide injection) at home. The presentations detailed a pilot study showing augmented decongestion with FUROSCIX compared to oral diuretics, and a study on re-examining brief hospitalizations for acute decompensated heart failure, suggesting an outpatient management alternative. These findings suggest that FUROSCIX could reduce costly hospital admissions and readmissions by allowing IV-equivalent diuresis at home.
scPharmaceuticals Inc. Announces Positive Results from the AT HOME-HF Phase 2 Pilot Study in Heart Failure
scPharmaceuticals Inc. announced positive results from its AT HOME-HF Phase 2 Pilot study for FUROSCIX, an investigational product for chronic heart failure patients. The study showed a positive trend for FUROSCIX over "treatment as usual," including a 37% reduction in heart failure hospitalizations and improvements in congestion symptoms and quality of life. The company anticipates a potential commercial launch in Q4 2022, pending FDA approval, given the strong value proposition demonstrated by these results.
scPharmaceuticals Inc. Announces Positive Results from the AT HOME-HF Phase 2 Pilot Study in Heart Failure
scPharmaceuticals Inc. announced positive results from its AT HOME-HF Phase 2 Pilot Study for FUROSCIX, an investigational treatment for heart failure. The study showed positive trends for FUROSCIX compared to "treatment as usual," including a 37% reduction in heart failure hospitalizations and improvements in congestion symptoms and quality of life. The company anticipates a Q4 2022 commercial launch of FUROSCIX, if approved, and highlighted its potential to optimize delivery of infused therapies and reduce healthcare costs.
scPharmaceuticals Inc. Announces Resubmission of FUROSCIX® New Drug Application
scPharmaceuticals Inc. announced the resubmission of its New Drug Application (NDA) for FUROSCIX® to the FDA for the treatment of decompensated heart failure, with a potential Q4 2022 commercial launch if approved. The company is advancing commercial readiness activities, including finalizing research, communicating data, and reinitiating staffing. This resubmission is a significant milestone as scPharmaceuticals transitions towards becoming a commercial stage company.
scPharmaceuticals Inc. Receives Complete Response Letter from FDA for FUROSCIX®
scPharmaceuticals Inc. announced it received a Complete Response Letter (CRL) from the FDA for its New Drug Application (NDA) for FUROSCIX®. The CRL cited the need for pre-approval inspections at two third-party manufacturing facilities delayed by travel restrictions, along with questions regarding testing, labeling, and combination product features. Despite the setback, the company plans to request a Type A meeting with the FDA to discuss a resubmission and remains committed to the potential of FUROSCIX® to prevent heart failure hospital admissions.
Tata Capital invests $4 mn in Brinton Pharma
Tata Capital Healthcare fund has invested $4 million (Rs 25.7 crore) for a minority equity stake in Brinton Pharmaceuticals Ltd. This investment aims to support Brinton's expansion into new therapeutic areas like pediatric and gynaecology, and to grow its international operations from eight to 32 countries. Brinton Pharmaceuticals also plans to cross Rs 300 crore in the dermatology segment by FY 2021.
Sun Pharma arm picks up 14.6 per cent stake in US company for $13 million
Sun Pharma's subsidiary has invested $13 million (about Rs 88 crore) to acquire a 14.58 percent stake in US-based scPharmaceuticals Inc. scPharmaceuticals focuses on developing pharmaceutical products for subcutaneous delivery. Following the news, Sun Pharma's stock saw a 2.59 percent increase on the BSE.
Sun Pharma picks up 14.6% stake in US based company for $13 million
Sun Pharma has invested $13 million in US-based scPharmaceuticals Inc., acquiring a 14.58% fully diluted equity stake. scPharmaceuticals Inc. is a pharmaceutical company focused on developing products for subcutaneous delivery. This investment follows Sun Pharma's recent announcement of plans to acquire the branded oncology product Odomzo from Novartis for $175 million.
